Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Rifampin and AMG 510 in Healthy Subjects
NCT05577624Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration (Cmax) of AMG 510 at Day 8, Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 510 at Day 8 and 1 more. Started Nov 2019; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05577624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577624.